Crescent Biopharma (CBIO) director receives grant of 11,050 stock options at $17.01

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. director Jonathan Violin received a grant of stock options covering 11,050 ordinary shares. The options carry an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Violin Jonathan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	11,050	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 11,050 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 11,050 options Exercise price: $17.01 per share Expiration date: June 2, 2036 +1 more

4 metrics

Option grant size 11,050 options Stock Option (Right to Buy) grant to director

Exercise price $17.01 per share Exercise price of stock options

Expiration date June 2, 2036 Option expiration for this grant

Post-grant derivative holdings 11,050 options Total options following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vests in full, annual meeting of shareholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "17.0100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"and vests in full on the earlier of (i) June 2, 2027"

annual meeting of shareholders financial

"or (ii) the date of the Issuer's next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 07:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Violin Jonathan

(Last)

(First)

(Middle)

C/O/ CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$17.01	06/02/2026		A		11,050		⁽¹⁾	06/02/2036	Ordinary Shares	11,050	$0	11,050	D

Explanation of Responses:

1. This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Barbara Bispham, as attorney-in-fact for Jonathan Violin	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CBIO director Jonathan Violin report?

Jonathan Violin reported receiving a grant of stock options for 11,050 ordinary shares of Crescent Biopharma. These options are a compensation-related award, not an open-market stock purchase or sale, and give him the right to buy shares at a fixed exercise price.

How many Crescent Biopharma (CBIO) options were granted to Jonathan Violin?

He was granted stock options over 11,050 ordinary shares of Crescent Biopharma. Following this grant, his reported derivative holdings from this award total 11,050 options, providing potential future equity exposure if the options vest and are later exercised.

What is the exercise price of Jonathan Violin’s CBIO stock options?

The options have an exercise price of $17.01 per share. This means Violin can buy Crescent Biopharma ordinary shares at $17.01 if he exercises the options after they vest and before they expire, regardless of the future market price at that time.

When do Jonathan Violin’s Crescent Biopharma stock options vest?

The options vest in full on the earlier of June 2, 2027 or the date of Crescent Biopharma’s next annual meeting of shareholders. Vesting is contingent on Violin’s continued service to the company through the applicable vesting date, according to the filing footnote.

When do Jonathan Violin’s CBIO stock options expire if unexercised?

The stock options are scheduled to expire on June 2, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to acquire Crescent Biopharma ordinary shares, even if they had previously vested under the award terms.

Is Jonathan Violin’s CBIO Form 4 transaction a stock purchase or sale?

The reported transaction is a grant of stock options, not a direct purchase or sale of shares. It reflects a compensation award giving Violin the right to buy shares at $17.01 in the future, subject to vesting and his continued service with Crescent Biopharma.